加载中
NASDAQHealthcareBiotechnology
最新数据
US$10.52
+US$0.22 · +2.14%
Monte Rosa Therapeutics, Inc. is a biopharmaceutical company dedicated to pioneering novel, small-molecule precision medicines. Their core approach involves leveraging the body's inherent mechanisms to precisely eliminate therapeutically relevant proteins. Among their key initiatives is an oral molecular glue degrader designed to target GSPT1, a specific translational termination factor and degron-containing protein, with the aim of treating Myc-driven cancers. The company's pipeline further includes programs for CDK2 in ovarian, uterine, and breast cancers, alongside NEK7 for addressing a spectrum of inflammatory conditions such as Crohn's disease, neurodegenerative ailments, diabetes, and liver disease. Moreover, VAV1 is being explored as a target for autoimmune disorders, and BCL11A, a protein holding significant therapeutic relevance, is under investigation for hemoglobinopathies. Founded in 2019, Monte Rosa Therapeutics, Inc. operates from its headquarters in Boston, Massachusetts.
收盘时
US$10.52
+US$0.22 · +2.14%
盘后
US$10.51
−US$0.01 · -0.10%
10月12日 19:30 ET
盘中时间采用ET。市场数据可能有所延迟。
Monte Rosa Therapeutics, Inc. is a biopharmaceutical company dedicated to pioneering novel, small-molecule precision medicines. Their core approach involves leveraging the body's inherent mechanisms to precisely eliminate therapeutically relevant proteins. Among their key initiatives is an oral molecular glue degrader designed to target GSPT1, a specific translational termination factor and degron-containing protein, with the aim of treating Myc-driven cancers. The company's pipeline further includes programs for CDK2 in ovarian, uterine, and breast cancers, alongside NEK7 for addressing a spectrum of inflammatory conditions such as Crohn's disease, neurodegenerative ailments, diabetes, and liver disease. Moreover, VAV1 is being explored as a target for autoimmune disorders, and BCL11A, a protein holding significant therapeutic relevance, is under investigation for hemoglobinopathies. Founded in 2019, Monte Rosa Therapeutics, Inc. operates from its headquarters in Boston, Massachusetts.
日内区间
当前US$10.52
52周区间
当前US$10.52
盘中时间采用ET。市场数据可能有所延迟。
Monte Rosa Therapeutics, Inc. is a biopharmaceutical company dedicated to pioneering novel, small-molecule precision medicines. Their core approach involves leveraging the body's inherent mechanisms to precisely eliminate therapeutically relevant proteins. Among their key initiatives is an oral molecular glue degrader designed to target GSPT1, a specific translational termination factor and degron-containing protein, with the aim of treating Myc-driven cancers. The company's pipeline further includes programs for CDK2 in ovarian, uterine, and breast cancers, alongside NEK7 for addressing a spectrum of inflammatory conditions such as Crohn's disease, neurodegenerative ailments, diabetes, and liver disease. Moreover, VAV1 is being explored as a target for autoimmune disorders, and BCL11A, a protein holding significant therapeutic relevance, is under investigation for hemoglobinopathies. Founded in 2019, Monte Rosa Therapeutics, Inc. operates from its headquarters in Boston, Massachusetts.
日内区间
当前US$10.52
52周区间
当前US$10.52
盈利能力占已公布营收的百分比。
营收
营业利润
净利润
| 项目（USD） | 2025财年 | 2024财年 | 2023财年 | 2022财年 | 2021财年 |
|---|---|---|---|---|---|
| 营收 | 1.24亿 USD | 7562.2万 USD | — | — | — |
| 销货成本 | 835.6万 USD | 812.1万 USD | 622.2万 USD | — | — |
| 毛利 | 1.15亿 USD | 6750.1万 USD | −622.2万 USD | — | — |
| 研究与开发 | 1.42亿 USD | 1.22亿 USD | 1.05亿 USD | 8506.1万 USD | 5715.5万 USD |
| 销售、一般及管理费用 | 3638万 USD | 3517.1万 USD | 3203.9万 USD | 2732.3万 USD | 1572.7万 USD |
| 营业费用 | 1.7亿 USD | 1.49亿 USD | 1.37亿 USD | 1.12亿 USD | 7288.2万 USD |
| 利息收入 | 1294.2万 USD | 1056.6万 USD | 933.4万 USD | 376.4万 USD | 4.6万 USD |
| 利息支出 | — | — | — | 376.4万 USD | — |
| 折旧和摊销 | 835.6万 USD | 812.1万 USD | 622.2万 USD | 374.5万 USD | 213.2万 USD |
| 营业利润 | −5420.8万 USD | −8111.2万 USD | −1.43亿 USD | −1.12亿 USD | −7288.2万 USD |
| 净利润 | −3862.6万 USD | −7270万 USD | −1.35亿 USD | −1.09亿 USD | −7395.8万 USD |
公司数据更新于 2026年10月13日。
近期已公布业绩
近期已公布业绩
第三方分析师预期可能变化，并非 GoAI 建议。
平均目标
US$24.83
上涨空间 136.03%报告持有此股票敞口的交易所交易基金。
Vanguard Morningstar Total Stock Market ETFVTI3570.54万0.00%2.3万亿 USD0.03%US$381.57-0.10%
State Street SPDR S&P Biotech ETFXBI2135.17万0.22%98.74亿 USD0.35%US$151.4-1.54%
iShares Russell 2000 ETFIWM1991.98万0.03%787.4亿 USD0.19%US$277.9-0.37%
Vanguard Extended Market ETFVXF1105.49万0.01%954亿 USD0.05%US$233.52-0.63%
iShares Russell 2000 Growth ETFIWO706.43万0.05%139.17亿 USD0.24%US$353.71-0.86%
Vanguard Russell 2000 ETFVTWO593万0.03%180亿 USD0.06%US$112.27-0.35%
Dimensional - US Small Cap ETFDFAS554.44万0.02%338.69亿 USD0.31%US$78.17-0.23%
iShares Biotechnology ETFIBB474.12万0.04%108.2亿 USD0.44%US$204.26-1.08%Vanguard Morningstar Total Stock Market ETFVTIState Street SPDR S&P Biotech ETFXBIiShares Russell 2000 ETFIWMVanguard Extended Market ETFVXFiShares Russell 2000 Growth ETFIWOVanguard Russell 2000 ETFVTWODimensional - US Small Cap ETFDFASiShares Biotechnology ETFIBBAI 生成内容及延迟市场数据仅供信息与教育用途，不构成投资建议。
